Biogen Inc.
HealthcareNASDAQ:BIIB · NASDAQ Global Select
+$0.09 today
Vol 0.84M · Avg 1.17M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
7.1%
avg 24.2%
ROIC
6.6%
avg 15.1%
ROA
4.4%
avg 12.2%
Analysis
ROE is currently the strongest return metric at 7.1% versus its period average of 24.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Christopher A. Viehbacher | President, Chief Executive Officer & Director | $5.28M | — | 65 | $38,015.00 | 0.03% |
Susan H. Alexander | Executive Vice President & Chief Legal Officer | $2.25M | — | 69 | $6,634.10 | <0.01% |
Nicole Murphy | Executive Vice President and Head of Pharmaceutical Operations & Technology | $2.01M | — | 53 | $10,560.00 | <0.01% |
Priya Singhal | Executive Vice President & Head of Development | $2.01M | — | 58 | $10,560.00 | <0.01% |
Robin C. Kramer | Executive Vice President & Chief Financial Officer | $1.63M | — | 60 | $8,450.00 | <0.01% |
Ginger Gregory | Executive Vice President & Chief Human Resources Officer | $1.59M | — | 58 | $8,025.00 | <0.01% |
Rachid Izzar | Executive Vice President and Head of Global Product Strategy & Commercialization | $1.27M | — | 51 | $7,390.00 | <0.01% |
Guy Hadari | Chief Information Officer | — | — | — | — | — |
Natacha Gassenbach | Chief Communication Officer & Head of Corporate Affairs | — | — | — | — | — |
Alisha A. Alaimo | President & Head of North America | — | — | — | — | — |
Fraser Hall | President & Head of Intercontinental Region | — | — | — | — | — |
Sean Godbout | VP, Chief Accounting Officer & Global Corporate Controller | — | — | 52 | $1,395.67 | <0.01% |
Tim Power | Head of Investor Relations | — | — | — | — | — |
Adam Keeney | Executive Vice President & Head of Corporate Development | — | — | 49 | $6,365.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$585.11
Sells
4
$1.03M
Net Sentiment
$1.03M
Net selling
Most Active
Singhal Priya
3 transactions
Analysis
Insiders reported 1 buys worth $585.11 and 4 sells worth $1.03M over the last 12 months. That adds up to net selling of $1.03M. Singhal Priya was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +38.6% | +1.9% (15yr)1 analysts |
| Revenue | N/A | N/A | +25.0% | +0.0% (15yr)8 analysts |
| Net Income | N/A | N/A | +37.0% | -1.1% (15yr)8 analysts |
| EBIT | N/A | N/A | +38.6% | -3.8% (15yr)8 analysts |
Analysis
Recent growth has been strongest in EPS at +38.6% over three years. Forward estimates point to EPS at +1.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Teva Pharmaceutical Industries Limited
NYSE:TEVA
$40.32B
DexCom, Inc.
NASDAQ:DXCM
$29.08B
Waters Corporation
NYSE:WAT
$23.17B
United Therapeutics Corporation
NASDAQ:UTHR
$23.17B
Quest Diagnostics Incorporated
NYSE:DGX
$22.48B
Labcorp Holdings Inc.
NYSE:LH
$21.83B
Incyte Corporation
NASDAQ:INCY
$21.68B
STERIS plc
NYSE:STE
$20.26B
Genmab A/S
NASDAQ:GMAB
$15.40B
Insulet Corporation
NASDAQ:PODD
$10.37B
Who manages BIIB?
Biogen Inc. (BIIB) lists 14 active executives. The top listed executive is Nicole Murphy, Executive Vice President and Head of Pharmaceutical Operations & Technology.
Are BIIB insiders buying or selling?
Recent insider activity shows net selling of $11.56M.
Explore More
Continue the stock analysis
Jump to another research area for this company.